Skip to main content

Breast Cancer Clinical Trials

Review the breast cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 451-475 of 899

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy
Status: Enrolling by Invitation
Location: 2 locations
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: Enrolling by Invitation
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Non-surgical Approach (Radiation Therapy) for the Treatment of Early Stage Breast Cancer Patients with an Exceptional Response to Neoadjuvant Chemotherapy, NoCUT-BC Trial
Status: Approved
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
A New Molecular Biomarker Test for Adapting Neoadjuvant Treatment in Patients with HER2-Positive Early-Stage Breast Cancer, EUREKA Trial
Status: Approved
Location: 9 locations
Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients with Minimal Residual Disease, MIRI Trial
Status: Approved
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Taletrectinib for the Treatment of Patients with CDH1-Mutated, Metastatic Invasive Lobular Breast Cancer, TaCe-1 Trial
Status: Approved
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients
Status: Approved
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Pulsed Electric Field Ablation for the Treatment of Metastatic Soft Tissue Lesions in Patients with Breast Cancer
Status: Approved
Location: University of California San Francisco, San Francisco, California
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Status: Temporarily Closed to Accrual
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in Patients with Breast Cancer
Status: Temporarily Closed to Accrual
Location: 4 locations
Pembrolizumab in Treating Patients with Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
ARX788 for Treating Patients with HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: University of California San Francisco, San Francisco, California
Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases
Status: Temporarily Closed to Accrual
Location: 3 locations
Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin for the Treatment of Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina
Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases
Status: Temporarily Closed to Accrual
Location: 2 locations
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
Onvansertib in Combination with Paclitaxel for the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: 3 locations
Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care
Status: Temporarily Closed to Accrual
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
Status: Temporarily Closed to Accrual
Location: See ClinicalTrials.gov
A Vaccine (H2NVAC) before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations
mRNA-2752 with or without a PD1 Inhibitor in Treating Patients with High Grade Ductal Breast Carcinoma In Situ
Status: Temporarily Closed to Accrual
Location: 2 locations
Autologous Anti-NY-ESO-1 TCR-Engineered T Cells for the Treatment of Patients with Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Status: Temporarily Closed to Accrual
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California